Trevi Therapeutics Inc 2025年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the quarterly period endedMarch 31,2025 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period fromtoCommission File Number:001-38886 TREVI THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware( State or other jurisdiction ofincorporation or organization) 45-0834299(I.R.S. EmployerIdentification No.) 195 Church Street,16 FloorNew Haven,Connecticut(Address of principal executive offices)th (203)304-2499(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Common Stock, $0.001 par value per share Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was requiredto submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒ Accelerated filer☐Smaller reporting company☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of April 30, 2025, the registrant had101,744,767shares of common stock, $0.001 par value per share, outstanding. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. Allstatements, other than statements of historical fact, contained in this Quarterly Report on Form 10-Q, including statementsregarding our strategy, future operations, future financial position, future revenues and profitability, projected costs, prospects,plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,”“estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similarexpressions are intended to identify forward-looking statements, although not all forward-looking statements contain theseidentifying words. The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about: •our clinical trials, including our ongoing Phase 2b CORAL clinical trial and our planned Phase 3 program of Haduvio forthe treatment of chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, our ongoing Phase 1 TIDAL studyto evaluate the effect of Haduvio on respiratory function and safety in patients with IPF of varying disease severity, ourplanned Phase 2a clinical trial of Haduvio for the treatment of chronic cough in patients with non-IPF interstitial lungdisease or non-IPF ILD, and our next clinical trial of Haduvio for the treatment of patients with refractory chronic cough,or RCC;•our plans to develop and, if approved, subsequently commercialize Haduvio for the treatment of chronic cough inpatients with IPF, chronic cough in patients with non-IPF ILD, and in patients with RCC;•our expectations regarding the timing for the initiation of clinical trials and the reporting of data from such trials;•the timing of and our ability to submit applications for and to obtain and maintain regulatory approvals for Haduvio;•our expectations regarding our ability to fund our operating expenses, including our ongoing and planned clinical trials,with our cash, cash equivalents and marketable securities;•our estimates regarding expenses, future revenue, timing of any future revenue, capital requirements and needs foradditional financing;•the impact of government laws and regulations;•our competitive position; and•our ability to establish and maintain collaborations. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and youshould not place undue reliance on